Adaptimmune Therapeutics (ADAP) Form 4 Adaptimmune Therapeutics / Charles Elliott Sigal ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Sigal Charles Elliott

(Last) (First) (Middle)

32 BREARLY ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptimmune Therapeutics PLC [ ADAP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
05/16/2016

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares with a nominal value of GBP0.001 per share(1)	05/16/2016		P		15,000(2)	A	$1.5(3)	269,100(4)	I	Shares held by Sigal Family Investments, LLC
Ordinary Shares with a nominal value of GBP0.001 per share(1)	05/17/2016		P		15,000(2)	A	$1.53(5)	284,100(6)	I	Shares held by Sigal Family Investments, LLC
Ordinary Shares with a nominal value of GBP0.001 per share(1)	05/18/2016		P		15,000(2)	A	$1.55(7)	299,100(8)	I	Shares held by Sigal Family Investments, LLC
Ordinary Shares with a nominal value of GBP0.001 per share								52,938(9)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Dr. Sigal is a manager of Sigal Family Investments, LLC. Dr. Sigal may be deemed to have voting and investment power over the shares held by Sigal Family Investments, LLC. Dr. Sigal disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

2. The 15,000 Ordinary Shares are represented by 2,500 American Depositary Shares ("ADSs") which are held by Sigal Family Investments, LLC. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc.

3. The price of $1.50 per Ordinary Share was derived from the purchase price paid on May 16, 2016, of $8.98 per ADS, divided by six.

4. The 269,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 15,000 Ordinary Shares represented by 2,500 ADSs.

5. The price of $1.53 per Ordinary Share was derived from the purchase price paid on May 17, 2016, of $9.18 per ADS, divided by six.

6. The 284,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 30,000 Ordinary Shares represented by 5,000 ADSs.

7. The price of $1.55 per Ordinary Share was derived from the purchase price paid on May 18, 2016, of $9.30 per ADS, divided by six.

8. The 299,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 45,000 Ordinary Shares represented by 7,500 ADSs.

9. The 52,938 Ordinary Shares are represented by 8,823 ADSs.

	/s/ Charles Elliott Sigal	05/18/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.